QUINTA-ANALYTICA have been approved for registration into the Ministère de l’Enseignement Supérieur et de la Recherche (France) Tax Credit system (CIR).

As a European based pharmaceutical company, Quinta are proud to have been granted approval into the French Tax Credit system for at least the next two years, opening the door for our French partners to take advantage of the R&D tax credit benefits offered by the Ministry of Research and Innovation.

The CIR is a public aid which supports the efforts of companies conducting Research and Development (fundamental research, applied research, experimental development) and also Innovation (expenditure for the production of prototypes or installations of new product pilots) via tax credit relief.

If you operate in France and are looking for a EU based partner who can deliver world class service and testing, get in touch to learn more about the tax incentives available to you and how you can offset your investment in research against your corporation tax bill.

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.